Despite CD8 T cells showing activation of anti-tumor immunity in MGMT-H tumors, previous studies have indicated that the achieved immune response is insufficient to control the growth of GBM based on clinical data (1, 29). The gene discussed is CD8A; the disease is glioblastoma.